Free Trial
NASDAQ:OCS

Oculis Q1 2025 Earnings Report

Oculis logo
$17.85 +0.05 (+0.28%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$17.84 -0.02 (-0.08%)
As of 08/22/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oculis EPS Results

Actual EPS
-$0.77
Consensus EPS
-$0.51
Beat/Miss
Missed by -$0.26
One Year Ago EPS
N/A

Oculis Revenue Results

Actual Revenue
$0.32 million
Expected Revenue
$0.22 million
Beat/Miss
Beat by +$100.00 thousand
YoY Revenue Growth
N/A

Oculis Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Oculis' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Oculis Earnings Headlines

This stock could leave NVDA in the dust
Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.tc pixel
Oculis Holding AG Reports Q2 2025 Financial Progress
See More Oculis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oculis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oculis and other key companies, straight to your email.

About Oculis

Oculis (NASDAQ:OCS), a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

View Oculis Profile

More Earnings Resources from MarketBeat